Temperaturowrazliwy mutant wirusa Herpes simplex typu 1. II. Neurowirulencja i latencja

• Autorzy: Litwinska B. , Trzcinska A. , Kantoch M.
• Języki publikacji: PL

Abstrakty

PL

U myszy zakażonych mutantem ts lub szczepem natywnym HSV-1 badano występowanie w komórkach nerwowych mózgu DNA oraz antygenów wirusowych w: fazie ostrego zakażenia; w odstępie 3-5 miesięcy po wprowadzeniu wirusa oraz u myszy poddanych jednocześnie immunosupresji. Uzyskane wyniki sugerują: brak, względnie obniżenie możliwości replikacji mutanta ts i wywoływania Iatencji w ośrodkowym układzie nerwowym myszy oraz że wprowadzenie immunosupresji zwiększa zdolność mutanta ts do wywołania zakażenia latentnego.

EN

The course of acute infection of mice with ts mutant or the native strain DNA and the antigens of HSV in brain nerve cells were determined. Virus DNA was detected in brains of all mice in both animal groups while the virus antigens - only in cells of mice infected with the native strain. It can be suggested, therefore, that the ability of ts mutant to replicate in central nervous system of the infected mice is lacking or much lower. The detection of virus nucleic acid 3-5 months after virus infection might indicate a possibility of establishing latent infection. However, ts mutant showed a significantly lower possibility of latency induction, as compared with highly virulent strains. It was found that the mutant ability to induce latent infection was markedly increased when mice were treated with both ts mutant and Depo-Medrol as immunosuppressive agent. This finding shows both a possibility of increase of frequency of Iatent infections in the state of immunosuppression, and of activation of the latent infection (reccurence of acute form of infection).

Słowa kluczowe

PL

mutanty; wirus herpes simplex typu 1; neurowirulencja; latencja; wirusy; wirusologia; preparat Depo-Medrol; wirulencja; myszy; immunogennosc; patogennosc; aktywnosc immunogenna

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2001
• Tom: 53
• Numer: 1
• Opis fizyczny: s.89-99,rys.,tab.,bibliogr.

Twórcy

autor

Litwinska B.

• Panstwowy Zaklad Higieny, 00-791 Warszawa, ul.Chocimska 24

autor

Trzcinska A.

autor

Kantoch M.

Bibliografia

• 1. Asano Y, Suga S, Yoshikawa T. Experience and reason: Twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics 1994; 94: 524-26.
• 2. Bastian OF, Rabson AS, Yee CL, Tralka TS. Herpesvirus hominis: isolation from human trigeminal ganglia. Science 1972; 178: 306-07.
• 3. Brunell PA, Taylor-Wiedeman J, Geiser CF. Risk of herpes zoster in children with leukaemia: varicella vaccine compared with history of chickenpox. Pediatrics 1986; 77: 53-56.
• 4. Burnett FM, Williams SW. Herpes simplex: A new point of view. Med J Aust 1939; 1: 637-42.
• 5. Fraser NW, Valyi-Nagy T. Viral, neuronal and immune factors which may influence herpes simplex latency and reactivation. Microb Pathog 1993; 15: 83-91.
• 6. Fraser NW, Spivack JG, Wróblewska Z i inni. A review of the molecular mechanisms of HSV-1 latency. Curr Eye Res 1991; 10 (suppl): 1-13.
• 7. Garcia-Blanco MA, Cullen BR. Molecular basis of latency in pathogenic human viruses. Science 1991; 254: 815-20.
• 8. Gershon A, Silverstein S. Live attenuated varicella vaccine for prevention of herpes zoster. Biologicals 1997; 25: 227-30.
• 9. Goodpasture EW. Herpetic infection with especial reference to involvment of the nervous system. Medicine (Baltimore) 1929; 8: 223-43.
• 10. Goodpasture EW, Teague O. Experimental production of herpetic lesions in organs and tissues of the rabbit. J Med Res 1923; 44: 121-33.
• 11. Grunert RR, McGahen JW, Davies WL. The in vivo antiviral activity of 1-adamantanamine (Amantadine). I. Prophylactic and therapeutic activity against influenza viruses. Virology 1965; 26: 262-69.
• 12. Gut W, Litwińska B. Przeciwciała dla wirusa odry w surowicy krwi osób, u których nie stwierdzono aktualnego zakażenia tym wirusem (lata 1984 - 1989). Przeg Epid 1991; XLV: 147-56.
• 13. Klein RJ, Kaley LA, Friedman-Kien AE. Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain. Vaccine 1984; 2: 219-23.
• 14. Lewis ME, Leung WC, Jeffrey VM, Warren KG. Detection of multiple strains of latent HSV-1 within individual human hosts. Abstracts, International Herpesvirus Workshop (Oxford, UK) 1983; str. 171.
• 15. Litwińska B, Sadowski W, Kańtoch M. HSV-1 infection and immunity in immunosuppressed mice. Acta Virol 1987; 31: 298-306.
• 16. Marshall GS, Plotkin SA. Cytomegalovirus vaccines. W: The Human Herpesviruses, red. Roizman, Whitley, Raven Press Ltd New York 1993.
• 17. McVoy MA, Adler SP. Immunologic evidence for frequent age-related cytomegalovirus reactivation in seropositive immunocompetent individuals. J Infect Dis 1989; 160: 1-10.
• 18. Meier JL, Straus SE. Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J Infect Dis 1992; 166 (suppl. 1): S13-S23.
• 19. Meignier B, Norrild B, Roizman B. Colonization of murine ganglia by a superinfecting strain of herpes simplex virus. Infect Immun 1983; 41: 702-08.
• 20. Stevens JG, Cook ML. Latent herpes simplex virus in spinal ganglia of mice. Science 1971; 173: 843-45.
• 21. Tenser RB, Hsiung GS. Pathogenesis of latent herpes simplex virus infection of the trigeminal ganglion in guinea pigs: effect of age, passive immunization and hydrocortisone. Infect Immun 1977; 16: 69-74.